Last reviewed · How we verify
Safinamide Methanesulfonate
Safinamide is a monoamine oxidase B (MAO-B) inhibitor that increases dopamine levels in the brain by blocking the enzyme responsible for dopamine breakdown.
Safinamide is a monoamine oxidase B (MAO-B) inhibitor that increases dopamine levels in the brain by blocking the enzyme responsible for dopamine breakdown. Used for Parkinson's disease as adjunctive therapy to levodopa in patients with motor fluctuations.
At a glance
| Generic name | Safinamide Methanesulfonate |
|---|---|
| Also known as | Xadago |
| Sponsor | Zambon SpA |
| Drug class | Monoamine oxidase B (MAO-B) inhibitor |
| Target | MAO-B (Monoamine oxidase B) |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
By inhibiting MAO-B, safinamide prevents the degradation of dopamine in the striatum, thereby increasing dopamine availability and enhancing motor function in Parkinson's disease patients. Additionally, safinamide has sodium channel blocking properties and may provide neuroprotective effects through modulation of glutamate release.
Approved indications
- Parkinson's disease as adjunctive therapy to levodopa in patients with motor fluctuations
Common side effects
- Dyskinesia
- Fall
- Impulse control disorder
- Nausea
- Headache
Key clinical trials
- Effect of Safinamide on Sleep Quality in Patients With Parkinson's Disease (PHASE4)
- Fall Risk Assessment in Parkinson's Disease Using Kinetikos Health
- A Study to Evaluate the Efficacy and Safety of Safinamide Mesilate as Add-on Therapy to Levodopa in Parkinson's Disease Participants With Motor Fluctuation in South Korea (PHASE4)
- An Observational Study on Safinamide, Rasagiline and Other Standard of Care in PD
- Overnight Switch From Rasagiline To Safinamide (PHASE4)
- A Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of Levodopa (PHASE3)
- Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)
- Effect of Safinamide on Parkinson's Disease Related Chronic Pain (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Safinamide Methanesulfonate CI brief — competitive landscape report
- Safinamide Methanesulfonate updates RSS · CI watch RSS
- Zambon SpA portfolio CI